Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy, Revascor, Regenerative Medicine Advanced Therapy designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome, a potentially life threatening congenital heart condition.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO: